Many patients describe feeling full sooner, needing smaller portions, or having quieter food noise persistent, intrusive thoughts about food reported by many patients with obesity
Side effects may briefly reappear with dose increases but resolve faster each time
119 These effects fit with the broader anti-inflammatory and cell protective actions of GLP-1 receptor agonists described throughout this review
March 2026: Eli Lilly announced topline results from the Phase 3 TRANSCEND-T2D-1 trial, reporting significant A1C reductions and weight loss in study subjects
Another study done with mice by Forst and colleagues, showed that binding of GLP-1 to the GLP-1 receptor in the myocardium leads to an increase in production of cAMP and activation of protein kinase A, which yields an increase in glucose uptake and the inotropic effects of the heart
The Wegovy tablet is not a supplement or a simple reformulation